Amwell reports Q1 EPS ($1.19), consensus ($1.88)

Reports Q1 revenue $66.83M, consensus $60.18M. “We had a strong Q1 across all our strategic initiatives. Together with our Leidos partners, we advanced our progress in the staged launch of our full solution across the Military Health System. We also made significant progress in our revenue quality and cost alignment measures,” said Ido Schoenberg, MD, chairman and CEO. “We are targeting meaningful margin expansion this year, and with another strong quarter of EBITDA improvement, we take a step closer to our goal of achieving cash flow breakeven from operations in 2026.”